Study summary · research use only
Novel orally active growth hormone secretagogues
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study describes a class of growth hormone-releasing compounds with molecular weights of 500 to 650, developed to obtain oral bioavailability. The abstract reports that the lead compound ipamorelin (4) was reduced in size, with backbone isosters incorporated to reduce hydrogen-bonding potential while retaining in vivo potency in swine. A rat pituitary assay screened all compounds, and selected ones were tested for in vivo potency in swine and oral bioavailability (fpo) in dogs. Most tested compounds had fpo in the range of 10-55%. The abstract states in vivo potency in swine after iv dosing was reported, with an ED50 of 30 nmol/kg of body weight for the most potent compound.
Abstract
A novel class of growth hormone-releasing compounds with a molecular weight in the range from 500 to 650 has been discovered. The aim of this study was to obtain growth hormone secretagogues with oral bioavailability. By a rational approach we were able to reduce the size of the lead compound ipamorelin (4) and simultaneously to reduce hydrogen-bonding potential by incorporation of backbone isosters while retaining in vivo potency in swine. A rat pituitary assay was used for screening of all compounds and to evaluate which compounds should be tested further for in vivo potency in swine and oral bioavailability, fpo, in dogs. Most of the tested compounds had fpo in the range of 10-55%. In vivo potency in swine after iv dosing is reported, and ED50 was found to be 30 nmol/kg of body weight for the most potent compound.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.